Patients Treated with ALL Therapy Inotuzumab Ozogamicin Report Better Quality of Life

Patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) who were treated with inotuzumab ozogamicin (InO) indicated better quality of life, functioning, and symptom scores compared with patients receiving standard-of-care chemotherapies.

Patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) who were treated with inotuzumab ozogamicin (InO) indicated better quality of life, functioning, and symptom scores compared with patients receiving standard-of-care chemotherapies, according to an analysis of patient-reported outcomes.

The phase III INO-VATE trial showed that patients who received InO had significantly higher complete response rates compared with standard-of-care chemotherapies. As part of the study, researchers assessed patient-reported outcomes (PROs) as a secondary objective of the study. The results of the assessed PROs were published in Cancer.

“In assessing the impact of a new agent, it also is crucial to assess QoL and other [PROs],” the authors wrote. “The value of such information in the measurement of a patient's subjective experience is becoming increasingly common during clinical trials as well as in routine care and follow‐up.”

In the study, the patients were randomized 1:1 to receive either InO or a standard-of-care therapy. Patients were to complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire and the EuroQoL Group 5 Dimensions Questionnaire on day 1 (baseline), on day 1 of each cycle of treatment, and, finally, at the end of treatment. The questionnaire completion rate was 78% with patients in the InO arm having a higher rate (85%) than the standard therapy arm (65%).

Click to continue reading on The American Journal of Managed Care.